prikaz prve stranice dokumenta Nintedanib treatment for bleomycin-induced lung injury - First report
  Download
PDF 1.89 MB
Scientific paper - Case study
Nintedanib treatment for bleomycin-induced lung injury - First report
Respiratory Medicine Case Reports, 46 (2023); 101921. https://doi.org/10.1016/j.rmcr.2023.101921
Rnjak, Dina; Batarilo Hađar, Martina; Pelicarić, Dubravka; Vukić, Tea; Janković Makek, Mateja; Samaržija, Miroslav; Hećimović, Ana

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Rnjak, D., Batarilo Hađar, M., Pelicarić, D., Vukić, T., Janković Makek, M., Samaržija, M. & Hećimović, A. (2023). Nintedanib treatment for bleomycin-induced lung injury - First report. Respiratory Medicine Case Reports, 46.. doi: 10.1016/j.rmcr.2023.101921

Rnjak, Dina, et al. "Nintedanib treatment for bleomycin-induced lung injury - First report." Respiratory Medicine Case Reports, vol. 46, 2023. https://doi.org/10.1016/j.rmcr.2023.101921

Rnjak, Dina, Martina Batarilo Hađar, Dubravka Pelicarić, Tea Vukić, Mateja Janković Makek, Miroslav Samaržija and Ana Hećimović. "Nintedanib treatment for bleomycin-induced lung injury - First report." Respiratory Medicine Case Reports 46 (2023). https://doi.org/10.1016/j.rmcr.2023.101921

Rnjak, D., et al. (2023) 'Nintedanib treatment for bleomycin-induced lung injury - First report', Respiratory Medicine Case Reports, 46. doi: 10.1016/j.rmcr.2023.101921

Rnjak D, Batarilo Hađar M, Pelicarić D, Vukić T, Janković Makek M, Samaržija M, and sur.. Nintedanib treatment for bleomycin-induced lung injury - First report. Respiratory Medicine Case Reports [Internet]. 2023 September 27 [cited 2024 November 22];46. doi: 10.1016/j.rmcr.2023.101921

D. Rnjak, et al., "Nintedanib treatment for bleomycin-induced lung injury - First report", Respiratory Medicine Case Reports, vol. 46, September 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:407335. [Accessed: 22 November 2024]

Metadata
Title (english)Nintedanib treatment for bleomycin-induced lung injury - First report
AuthorDina Rnjak
AuthorMartina Batarilo Hađar
AuthorDubravka Pelicarić
AuthorTea Vukić
AuthorMateja Janković Makek
AuthorMiroslav Samaržija
AuthorAna Hećimović
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients. The optimal treatment for bleomycin lung toxicity has not been established and no clinical trials have been performed. Here we present first successful case report of nintedanib therapy in a patient with bleomycin-induced lung injury (BILI). The prevention, early diagnosis, and management of bleomycin pulmonary toxicities are essential, clinical trials are needed in this area.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleRespiratory Medicine Case Reports
Numberingvol. 46, 101921
p-ISSN2213-0071
DOIhttps://doi.org/10.1016/j.rmcr.2023.101921
URN:NBNurn:nbn:hr:105:407335
Publication2023-09-27
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S2213007123001168
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2024-05-17 08:44:23